Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Gilead Sciences Inc Market Cap
From what 14 stock analysts predict, the share price for Gilead Sciences Inc (GILD) might increase by 20.22% in the next year. This is based on a 12-month average estimation for GILD. Price targets go from $75.00 to $105.00. The majority of stock analysts believe GILD is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 14 Wall Street analysts have assignedGILD 7 buy ratings, 7 hold ratings, and 0 sell ratings. This means that analysts expect Gilead Sciences Inc to hold. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on GILD. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| hartaj singh Oppenheimer | Buy | $105.0 | maintained | Feb 16, 2024 |
| geoff meacham Bank of America Securities | Buy | $95.0 | initiatedcoverage | Feb 16, 2024 |
| michael okunewitch Maxim Group | Buy | $90.0 | maintained | Feb 13, 2024 |
| joseph catanzaro Piper Sandler | Buy | $95.0 | rated | Feb 13, 2024 |
| salim syed Mizuho Securities | Buy | $101.0 | maintained | Feb 12, 2024 |
| evan seigerman BMO Capital | Buy | $89.0 | rated | Feb 7, 2024 |
| michael yee Jefferies | Buy | $95.0 | maintained | Feb 6, 2024 |
| chris schott J.P. Morgan | Buy | None | maintained | Jan 22, 2024 |
| umer raffat Evercore ISI | Buy | None | maintained | Jan 22, 2024 |
| tyler van buren TD Cowen | Buy | $95.0 | maintained | Nov 7, 2023 |
| robyn karnauskas Truist Financial | Buy | $91.0 | maintained | Nov 7, 2023 |
| sasikarn udomvej DBS | Buy | $87.0 | maintained | Jul 3, 2023 |
| jasper hellweg Argus Research | Buy | $90.0 | maintained | Jun 2, 2023 |
| do kim Piper Sandler | Buy | $112.0 | maintained | Feb 3, 2023 |
| jason mccarthy Maxim Group | Buy | $84.0 | maintained | Feb 3, 2022 |
| david toung Argus Research | Buy | $75.0 | upgraded | Jan 28, 2022 |
| geoff porges SVB Securities | Buy | None | maintained | Dec 12, 2021 |
| robert driscoll Wedbush | Buy | $67.0 | maintained | Nov 19, 2021 |
| aaron gal Bernstein | Buy | $80.0 | upgraded | Apr 1, 2021 |
| louise pearson Redburn Partners | Buy | None | upgraded | Mar 29, 2021 |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc., and Tentarix Biotherapeutics Inc., as well as a partnership with Assembly Biosciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was incorporated in 1987 and is headquartered in Foster City, California.
When did it IPO
1992
Staff Count
17,000
Country
United States
Sector/Industry
Healthcare/Drug Manufacturers - General
CEO
Mr. Daniel P. O'Day
Market Cap
$89.76B
In 2023, GILD generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that GILD's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
KLAC-USD
$651.85
$79.5
ABNB-USD
$155.26
ADI-USD
$191.91
MDLZ-USD
$71.98
EQIX-USD
$864.73
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
